Company Team Projects Media Contact


Investing in biomedical discoveries

LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.




Combioxin announced that CAL02 showed positive safety profile at high dose in the CAL02-001 clinical trial in pneumonia patients - 10/10/2017

Abionic receives CE Mark for most rapid sepsis diagnostic test based on PSP, moving LASCCO's biomarker to market - 09/01/2017